🇺🇸 FDA
Patent

US 11959081

Transthyretin (TTR) iRNA compositions and methods of use thereof

granted A61KA61K31/713

Quick answer

US patent 11959081 (Transthyretin (TTR) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/713